The DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays
Open accessAbstract
In its early years, mass spectrometry (MS)‐based proteomics focused on the cataloging of proteins found in different species or different tissues. By 2005, proteomics was being used for protein quantitation, typically based on “proteotypic” peptides which act as surrogates for the parent proteins. Biomarker discovery is usually done by non‐targeted “shotgun” proteomics, using relative quantitation methods to determine protein expression changes that correlate with disease (output given as “up‐or‐down regulation” or “fold‐increases”). MS‐based techniques can also perform “absolute” quantitation which is required for clinical applications (output given as protein concentrations). Here we describe the differences between these methods, factors that affect the precision and accuracy of the results, and some examples of recent studies using MS‐based proteomics to verify cancer‐related biomarkers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anderson, N. L., & Anderson, N. G. (2002) · Molecular & Cellular Proteomics · doi:10.1074/mcp.r200007-mcp200 · Cited by 4,414
Ross, P. L., Huang, Y. N., Marchese, J. N., Williamson, B., Parker, K., Hattan, S., Khainovski, N., Pillai, S., Dey, S., Daniels, S., et al. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400129-mcp200 · Cited by 4,401
Protein biomarker discovery and validation: the long and uncertain path to clinical utility
Rifai, N., Gillette, M. A., & Carr, S. A. (2006) · Nature Biotechnology · doi:10.1038/nbt1235 · Cited by 1,867 · cited 4×
“…viewed as a series of preclinical phases e biomarker discovery, and verification e before the final clinical evaluation (Paulovich et al., 2008; Rifai et al., 2006; Rodriguez et al., 2010a; Surinova et al., 2011) The inverse relationship between the number of samples analyzed and the number of…”
BackgroundInfluentialMass spectrometry–based proteomics turns quantitative
Ong, S.-E., & Mann, M. (2005) · Nature Chemical Biology · doi:10.1038/nchembio736 · Cited by 1,572 · cited 2×
“MRM with SIS peptides is considered to be the “gold standard” MS-based quantitation method (Ong and Mann, 2005), and”
MethodSelected reaction monitoring–based proteomics: workflows, potential, pitfalls and future directions
Picotti, P., & Aebersold, R. (2012) · Nature Methods · doi:10.1038/nmeth.2015 · Cited by 1,302
Addona, T. A., Abbatiello, S. E., Schilling, B., Skates, S. J., Mani, D. R., Bunk, D. M., Spiegelman, C. H., Zimmerman, L. J., Ham, A.-J. L., Keshishian, H., et al. (2009) · Nature Biotechnology · doi:10.1038/nbt.1546 · Cited by 1,037
Self-citationDepletion of Abundant Plasma Proteins and Limitations of Plasma Proteomics
Tu, C., Rudnick, P. A., Martinez, M. Y., Cheek, K. L., Stein, S. E., Slebos, R. J. C., & Liebler, D. C. (2010) · Journal of Proteome Research · doi:10.1021/pr100646w · Cited by 390
On the Development of Plasma Protein Biomarkers
Surinova, S., Schiess, R., Hüttenhain, R., Cerciello, F., Wollscheid, B., & Aebersold, R. (2011) · Journal of Proteome Research · doi:10.1021/pr1008515 · Cited by 334 · cited 4×
“During the 15 or so years since its inception, mass spectrometry (MS) -based proteomics has led to the discovery and et al. (Surinova et al., 2011), and used with permission.”
BackgroundMethodInfluentialRudnick, P. A., Clauser, K. R., Kilpatrick, L. E., Tchekhovskoi, D. V., Neta, P., Blonder, N., Billheimer, D. D., Blackman, R. K., Bunk, D. M., Cardasis, H. L., et al. (2010) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m900223-mcp200 · Cited by 183
(2013) · Nature Methods · doi:10.1038/nmeth.2329 · Cited by 107
Cited by
Revisiting biomarker discovery by plasma proteomics
Geyer, P. E., Holdt, L. M., Teupser, D., & Mann, M. (2017) · Molecular Systems Biology · doi:10.15252/msb.20156297 · Cited by 917
Precision diagnostics: moving towards protein biomarker signatures of clinical utility in cancer
Borrebaeck, C. A. K. (2017) · Nature Reviews Cancer · doi:10.1038/nrc.2016.153 · Cited by 435
Nakayasu, E. S., Gritsenko, M., Piehowski, P. D., Gao, Y., Orton, D. J., Schepmoes, A. A., Fillmore, T. L., Frohnert, B. I., Rewers, M., Krischer, J. P., et al. (2021) · Nature Protocols · doi:10.1038/s41596-021-00566-6 · Cited by 275
Meyer, J. G., & Schilling, B. (2017) · Expert Review of Proteomics · doi:10.1080/14789450.2017.1322904 · Cited by 151
Systems-based proteomics to resolve the biology of Alzheimer’s disease beyond amyloid and tau
Rayaprolu, S., Higginbotham, L., Bagchi, P., Watson, C. M., Zhang, T., Levey, A. I., Rangaraju, S., & Seyfried, N. T. (2021) · Neuropsychopharmacology · doi:10.1038/s41386-020-00840-3 · Cited by 118
Metadata
- Authors
- Parker, C. E., & Borchers, C. H.
- Venue
- Molecular Oncology
- Publisher
- Wiley
- Published
- 2014-03-20
- Volume
- 8
- Issue
- 4
- Pages
- 840-858
- ISSN
- 1574-7891 (ISSN-L)
- 1878-0261
- OpenAlex
- W2116355203
- Cited by
- 238
- References
- 10
- FWCI
- 9.52
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays. https://app.cochat.ai/papers/10.1016/j.molonc.2014.03.006
- The paper
- Parker, C. E., & Borchers, C. H. (2014). Mass spectrometry based biomarker discovery, verification, and validation — Quality assurance and control of protein biomarker assays. Molecular Oncology. https://doi.org/10.1016/j.molonc.2014.03.006
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.